BioCentury
ARTICLE | Clinical News

ALD-101: Development discontinued

May 10, 2010 7:00 AM UTC

Aldagen disclosed in an SEC filing that in January it discontinued development of lead candidate ALD-101 to improve cord blood transplantation in pediatric patients with inherited metabolic disorders. The company said the agency was unlikely to accept the use of historical controls from a Phase I trial of ALD-101 as a comparator in a Phase III trial, which the company has terminated. The company concluded that further development was not a "prudent use of resources." ALD-101 is a mix of stem and progenitor cells isolated from the 20% fraction of a banked cord blood unit. ...